Here are the 424B prospectus supplements from Arcus Biosciences, Inc. (RCUS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow RCUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RCUS filings page.
Arcus Biosciences, Inc. (RCUS) is offering 14,285,715 shares of common stock at $17.50 per share, with estimated net proceeds of approximately $234.5 million after underwriting discounts and estimated expenses. The underwriters may purchase up to 2,142,857 additional shares under an option exercisable for 30 days from the prospectus supplement date; full exercise would bring estimated net proceeds to approximately $269.7 million.
Arcus plans to use the proceeds for ongoing research and development, including expanding and accelerating clinical development of casdatifan, and for working capital, operating expenses and other general corporate purposes. The company estimated approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026; this preliminary unaudited estimate is subject to completion of closing procedures and management review.
The prospectus states immediate net tangible book value dilution to new investors of $12.56 per share, or $12.39 per share if the underwriters exercise their option in full. Arcus had 127,018,631 shares of common stock outstanding as of June 30, 2026.
Arcus Biosciences, Inc. proposes a primary offering of common stock under its shelf registration, with proceeds payable to the company. The preliminary prospectus supplement is subject to completion.